Alvogen has launched a generic version of Celgene’s Revlimid (lenalidomide) in “a range” of central and eastern European (CEE) markets including Bulgaria, Croatia, Romania and the Baltic states. Alvogen’s version – developed in-house by its Lotus Pharmaceuticals subsidiary – will be available as 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules.
“Following the launch into CEE,” Alvogen said, “the generic and bioequivalent version of Revlimid will be launched globally in 2019.”...




